This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
marijuana: Archive
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
by Sundeep Ganoria
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.
CRONPositive Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical pot-stocks
GTBIF Stock Climbs 17.5% in Three Months: Time to Invest or Cash Out?
by Sundeep Ganoria
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
GTBIFPositive Net Change CRLBFPositive Net Change TRLVPositive Net Change
marijuana medical pot-stocks
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
by Sundeep Ganoria
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
GTBIFPositive Net Change CRLBFPositive Net Change VRNOPositive Net Change
marijuana medical pot-stocks
Sin Stocks Under the Microscope: Risks, Returns & Reality
by Rajani Lohia
Sin stocks, including alcohol, tobacco, cannabis, firearms and gambling, draw investors' attention with steady demand and dividends, but ESG pressure, taxes and regulation are reshaping the risk/reward.
MONegative Net Change MCRIPositive Net Change SAMNegative Net Change CHDNPositive Net Change TPBNegative Net Change
consumer-staples marijuana thematic tobacco
Verano Advances U.S. Exchange Uplisting Plans: Time to Invest?
by Sundeep Ganoria
VRNO's reverse split and prior U.S. redomestication support potential exchange uplisting plans as the company expands stores and product offerings.
GTBIFPositive Net Change CURLFPositive Net Change VRNOPositive Net Change
marijuana medical pot-stocks
Curaleaf Prepares for US Exchange Uplisting: Time to Invest?
by Sundeep Ganoria
CURLF's reverse stock split and Delaware domestication plan signal preparation for a potential U.S. uplisting as revenue and international growth improve.
TLRYPositive Net Change GTBIFPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
What IIPR's $282M Senior Note Repayment Means for Investors in 2026
by Zacks Equity Research
IIPR repays $282M of 5.50% notes due May 2026, easing refinancing pressure and boosting flexibility as it leans on new secured loans.
STAGPositive Net Change IIPRNegative Net Change ILPTNegative Net Change
finance marijuana reit
Should You Buy CGC Stock After Marijuana Reclassification?
by Sundeep Ganoria
Canopy Growth gains attention as marijuana reclassification boosts cannabis sentiment, but margin pressure and execution risks persist.
CGCNo Net Change ACBPositive Net Change SNDLPositive Net Change
marijuana medical pot-stocks
US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
by Aparajita Dutta
Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.
YOLOPositive Net Change CNBSPositive Net Change MSOSPositive Net Change WEEDPositive Net Change
etfs marijuana
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
by Sundeep Ganoria
JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.
JAZZPositive Net Change TLRYPositive Net Change VRNOPositive Net Change
biotechs marijuana medical pot-stocks